Neopharm KRX:092730KOSDAQ
네오팜 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked9since Sep 11
In Q2 2026, Neopharm reported revenue of ₩43.6bn, up 36.2% year on year, and operating profit of ₩9.8bn. Neopharm (네오팜) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Revenue +30% Revenue & profit growth Op. margin 20%+ Screener
Neopharm quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩43.6bn | +36.2% | ₩9.8bn margin 22.5% | ₩8.4bn |
| Q1 2026 | ₩36.2bn | +14.6% | ₩8.7bn margin 24.0% | ₩8.6bn |
| Q4 2025 derived | ₩36.4bn | +7.0% | ₩7.2bn margin 19.8% | ₩6.8bn |
| Q3 2025 | ₩32.2bn | +23.1% | ₩6.8bn margin 21.0% | ₩6.9bn |
| Q2 2025 | ₩32.0bn | +4.4% | ₩7.0bn margin 21.9% | ₩7.1bn |
| Q1 2025 | ₩31.6bn | +12.0% | ₩7.8bn margin 24.6% | ₩7.1bn |
| Q4 2024 derived | ₩34.0bn | +25.0% | ₩6.7bn margin 19.6% | ₩6.7bn |
| Q3 2024 | ₩26.2bn | +19.9% | ₩5.1bn margin 19.4% | ₩4.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Neopharm top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Neopharm news Korean headlines
-
네오팜 제로이드, 10월 오프라인 현장 접점 확대… 홍대 팝업·러닝 페스티벌 전개
2 more on this story · 2 outlets
- 네오팜 제로이드, 홍대 팝업·러닝 페스티벌로 오프라인 접점 확대스페셜타임스 · Oct 2 10:26
- 네오팜 제로이드, 홍대·러닝 페스티벌서 오프라인 접점 확대파이낸셜투데이 · Oct 2 13:52
-
네오팜 리얼베리어, 독자 성분 프로세라 개발해 익스트림 프로세라 4종 출시
1 more on this story · 1 outlets
- 네오팜 리얼베리어, ‘프로세라™’ 적용 ‘익스트림 프로세라’ 4종 출시디스커버리뉴스 · Sep 29 10:30